Thursday, December 9, 2021

Bharat Biotech Covaxin shows 77.8 percent efficacy against ‘Delta Variant’, says Lancet

Hyderabad-based Bharat Biotech Company limited has claimed that its Covaxin, has shown 77.8 percent efficacy against COVID-19 during the Phase-3 data. The Company in a release has quoted the Lancet peer-review stating that Phase-3 data shows 77.8 percent efficacy against the patients symptomatic with the infectious disease. WHO has recently granted Covaxin the emergency use authorization and the shot has already been cleared for use in as many as 17 nations across the world.

The peer-review of Lancet journal has now corroborated  Bharat Biotech’s efficacy analysis regarding Covaxin and confirmed that the shot also demonstrates 77.8 percent efficacy against patients symptomatic with infectious disease. In the new study, the Lancet noted that the COVID-19 vaccine made by Bharat Biotech is highly efficacious and presents no safety concern, also inducing a robust antibody response two weeks after two doses of the shot are administered. The journal also noted that more research is needed to understand more about Covaxin’s long-term safety and effectiveness, as well as protection against hospitalization. It was also observed that only 684 suspected COVID-19 cases were identified at least 14 days after the second dose, among the total 24,419 participants who received both doses of the vaccine. The vaccine was found to be over 93 percent effective against severe symptomatic cases of COVID-19.

The Phase-3 trials for Covaxin were conducted on 25,798 subjects – aged between 18 to 98 years – across 25 sites in the country.

- Advertisement -spot_img
Latest news
Related news